{"id":"azd0780","safety":{"commonSideEffects":[{"rate":null,"effect":"Sedation"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"AZD0780 binds to GABA-A receptors and increases the frequency of chloride channel opening in response to GABA, thereby potentiating GABAergic inhibitory signaling. This mechanism is intended to reduce seizure activity and provide rapid symptom relief in acute seizure conditions. The selective modulation profile aims to provide efficacy while minimizing sedation and other off-target effects associated with non-selective GABA-A modulators.","oneSentence":"AZD0780 is a selective GABA-A receptor positive allosteric modulator that enhances inhibitory neurotransmission in the central nervous system.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:13.118Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute seizures or seizure clusters"},{"name":"Status epilepticus (investigational)"}]},"trialDetails":[{"nctId":"NCT07218900","phase":"PHASE2","title":"A Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density Lipoprotein Cholesterol Levels (LDL-C) in Adult Participants With Dyslipidaemia","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-13","conditions":"Dyslipidaemia","enrollment":76},{"nctId":"NCT06834932","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-12-06","conditions":"Dyslipidaemia","enrollment":360},{"nctId":"NCT07423598","phase":"PHASE1","title":"A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics With AZD0780 Following Repeated Dose Administration in Healthy Adults With Elevated LDL-C Levels","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-02-24","conditions":"Healthy Participants","enrollment":40},{"nctId":"NCT07000357","phase":"PHASE3","title":"A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-06-04","conditions":"Cardiovascular Disease","enrollment":15100},{"nctId":"NCT06692764","phase":"PHASE2","title":"A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-10-30","conditions":"Atherosclerotic Cardiovascular Disease","enrollment":202},{"nctId":"NCT07000123","phase":"PHASE3","title":"A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2025-05-28","conditions":"Cardiovascular Disease","enrollment":3046},{"nctId":"NCT07000136","phase":"PHASE3","title":"A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2025-06-10","conditions":"Heterozygous Familial Hypercholesterolaemia","enrollment":455},{"nctId":"NCT07216131","phase":"PHASE1","title":"A Study to Investigate the Effect of AZD0780 on Metformin Pharmacokinetics in Healthy Adult Volunteers Aged 18 to 55 Years","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2025-11-10","conditions":"Healthy Participants","enrollment":14},{"nctId":"NCT06173570","phase":"PHASE2","title":"A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-01-19","conditions":"Dyslipidemia","enrollment":428},{"nctId":"NCT06742853","phase":"PHASE1","title":"A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-12-20","conditions":"Dyslipidemia","enrollment":81},{"nctId":"NCT05817461","phase":"PHASE1","title":"An ADME Study of [14C]AZD0780 in Healthy Male Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-04-19","conditions":"Cardiovascular Diseases","enrollment":8},{"nctId":"NCT05787002","phase":"PHASE1","title":"A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-03-09","conditions":"Dyslipidemia","enrollment":16},{"nctId":"NCT06671405","phase":"PHASE1","title":"An Open-label Study in Healthy Participants to Evaluate AZD0780 as an Object or Precipitant of CYP3A4-mediated Drug-drug Interactions","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-09-25","conditions":"Dyslipidaemia","enrollment":59},{"nctId":"NCT06592482","phase":"PHASE1","title":"A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-08-02","conditions":"Renal Impairment","enrollment":30},{"nctId":"NCT06576765","phase":"PHASE1","title":"Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-08-08","conditions":"Hepatic Impairment","enrollment":16},{"nctId":"NCT05384262","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-05-18","conditions":"Dyslipidemia","enrollment":183}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Dose 1","AZD0780"],"phase":"phase_3","status":"active","brandName":"AZD0780","genericName":"AZD0780","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AZD0780 is a selective GABA-A receptor positive allosteric modulator that enhances inhibitory neurotransmission in the central nervous system. Used for Acute seizures or seizure clusters, Status epilepticus (investigational).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}